Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
$0.00
-60.0%
$0.00
$0.00
$0.05
$11K39.0912,383 shs102,251 shs
BOPH
Bohai Pharmaceuticals Group
$0.00
$0.00
$0.00
$0.00
$20K1.7830,425 shs50,000 shs
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.18
$0.00
$2.96
$10K-26.41250 shsN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
$0.00
$0.00
$0.21
$36KN/A26,223 shs2,000 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
-60.00%-99.60%+100.00%+100.00%-98.00%
BOPH
Bohai Pharmaceuticals Group
0.00%0.00%0.00%0.00%0.00%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%-99.95%-99.95%-99.97%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
$0.00
-60.0%
$0.00
$0.00
$0.05
$11K39.0912,383 shs102,251 shs
BOPH
Bohai Pharmaceuticals Group
$0.00
$0.00
$0.00
$0.00
$20K1.7830,425 shs50,000 shs
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$0.18
$0.00
$2.96
$10K-26.41250 shsN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
$0.00
$0.00
$0.21
$36KN/A26,223 shs2,000 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
-60.00%-99.60%+100.00%+100.00%-98.00%
BOPH
Bohai Pharmaceuticals Group
0.00%0.00%0.00%0.00%0.00%
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00%0.00%-99.95%-99.95%-99.97%
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
0.00
N/AN/AN/A
BOPH
Bohai Pharmaceuticals Group
0.00
N/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
0.00
N/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/AN/AN/A
BOPH
Bohai Pharmaceuticals Group
N/AN/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
$110K0.00N/A0.02N/ANaN
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
-$30.37MN/A0.00N/AN/AN/AN/AN/A
BOPH
Bohai Pharmaceuticals Group
N/AN/A0.00N/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
-$410K-$0.020.00N/AN/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
N/AN/AN/AN/AN/A
BOPH
Bohai Pharmaceuticals Group
N/AN/AN/AN/AN/A
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
N/AN/AN/AN/AN/A
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
N/AN/AN/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aridis Pharmaceuticals, Inc. stock logo
ARDS
Aridis Pharmaceuticals
3053.32 million50.39 millionNot Optionable
BOPH
Bohai Pharmaceuticals Group
N/A19.52 millionN/ANot Optionable
China Health Industries Holdings, Inc. stock logo
CHHE
China Health Industries
4064.95 million44.62 millionNot Optionable
NephroGenex, Inc stock logo
NRXGQ
NephroGenex
1,70012.95 millionN/ANot Optionable

Recent News About These Companies

Habib Kairouz's Net Worth
Elicera Therapeutics AB (ELIC)
LL Lucky Games publ AB (LADYLU)
Xinjiang Daqo New Energy Co Ltd (688303)
Tsukuba Bank Ltd (8338)
PEXA Group Ltd (PXA)
Kosei Securities Co Ltd (8617)
Nusatama Berkah Tbk PT (NTBK)
Olympic Group Corp (8289)
Shandong Sanyuan Biotechnology Co Ltd (301206)
Okinawa financial Group Inc (7350)
Selvas Healthcare Inc (208370)
Al-Bad Massuot Yitzhak Ltd (ALBA)
Seven Utilities and Power PCL (7UP)
Yong Pyong Resort Corp (070960)
Aksa Enerji Uretim AS (AKSEN)
MHP Hotel AG (CDZ0)
Aridis Pharmaceuticals stock logo

Aridis Pharmaceuticals NASDAQ:ARDS

$0.0002 0.00 (-60.00%)
As of 09/8/2025 12:39 PM Eastern

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Bohai Pharmaceuticals Group OTCMKTS:BOPH

$0.0010 0.00 (0.00%)
As of 03/11/2019

Bohai Pharmaceuticals Group, Inc. engages in the production, manufacture, and distribution of herbal pharmaceuticals based on traditional Chinese medicine. Its products include lung nourishing syrup, tongbi capsules, tongbi tablets, zhuangyuanshenhailong medicinal wine, bazhenyimu cream, fangfengtongsheng granule, and zhengxintai capsules. The company was founded on January 9, 2008 and is headquartered in Yantai, China.

China Health Industries stock logo

China Health Industries OTCMKTS:CHHE

China Health Industries Holdings, Inc., through its subsidiaries, manufactures and sells health products. The company operates through three segments: Humankind, HLJ Huimeijia, and Others. The company offers hemp derivative products, such as hemp oil, hemp protein powder, hemp polypeptides, collagen peptides, hemp essence repair lotions, hemp revitalizing essence products, hemp anti-aging brightening eye creams, hemp frozen age nourishing creams, hemp seed beers, and hemp seeds. It also provides health supplements, including Sailuozhi soft capsule, which is made from frog oil, soybean isoflavone, procyanidine, and vitamin E for freckle removal and skin moisture supplements under the QunLe brand; and propolis and black ant capsule that is made from propolis, black ant, acanthopanax, and astragalus root under the Kindlink brand. In addition, the company offers health products for acne removal, relieving eyestrain, enhancing bone density, enhancing memory, enhancing nutritional anemia and chloasma, relaxing bowels and promoting the discharge of lead, enhancing immunity and relieving physical fatigue, and dispelling chloasma, as well as iron and multivitamin, and mineral supplements. Further, it manufactures and sells various types of medical drugs, such as enema glycerini, umguentumacidi borici camphoratum, ge hong beriberi water, pelvic inflammation suppository, injury and paralysis tincture, indometacin and furazolidone suppositories, injury and rheumatism relieving paste, refining goupi cream, muskiness pain relieving paste, muskiness bone strengthener paste, matrine suppositories, ethacriding lactate solution, iodine tincture, mercurochrome solution, hydrogen peroxide solution, halcinonide cream, compound fluocinonide tincture, and policresulen vaginal suppository. The company primarily sells its products through sales personnel and sales agents. China Health Industries Holdings, Inc. was founded in 1996 and is based in Harbin City, the People's Republic of China.

NephroGenex stock logo

NephroGenex OTCMKTS:NRXGQ

NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.